Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP


Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
08 2019
Historique:
received: 21 11 2018
revised: 27 03 2019
accepted: 29 04 2019
pubmed: 13 5 2019
medline: 23 7 2020
entrez: 13 5 2019
Statut: ppublish

Résumé

Recent work has delineated key differences in the antigen processing and presentation mechanisms underlying HLA-DP alleles encoding glycine at position 84 of the DPβ chain (DP

Identifiants

pubmed: 31078377
pii: S0896-8411(18)30682-6
doi: 10.1016/j.jaut.2019.04.023
pii:
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B, Member 3 0
Antigens 0
Calreticulin 0
HLA-DP Antigens 0
Histocompatibility Antigens Class I 0
Membrane Transport Proteins 0
Molecular Chaperones 0
tapasin 0
Calnexin 139873-08-8
TAP2 protein, human 145892-13-3
Proteasome Endopeptidase Complex EC 3.4.25.1
Protein Disulfide-Isomerases EC 5.3.4.1
PDIA3 protein, human EC 5.3.4.1.

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-125

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Mark Anczurowski (M)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.

Kenji Sugata (K)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Yukiko Matsunaga (Y)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Yuki Yamashita (Y)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Chung-Hsi Wang (CH)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.

Tingxi Guo (T)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Kenji Murata (K)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Hiroshi Saijo (H)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Yuki Kagoya (Y)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Kayoko Saso (K)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada.

Marcus O Butler (MO)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.

Naoto Hirano (N)

Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. Electronic address: naoto.hirano@uhnresearch.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH